Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Grazoprevir/Elbasvir Treatment in Liver or Kidney Transplant Recipients with Genotype 1b Hepatitis C Virus Infection.

Antimicrobial agents and chemotherapy - 15 Feb 2022

Lai Ping-Chin, Chen Cheng-Hsu, Jeng Long-Bin, Yu Tung-Min, Tsai Shang-Feng, Wu Ming-Ju, Cheng Shao-Bin, Yang Sheng-Shun, Lee Teng-Yu

Abstract excerpt

More options regarding the choice of direct-acting antivirals (DAAs) are helpful for avoiding individual limitations in treating hepatitis C virus (HCV) infection. We aimed to assess the efficacy and tolerability of grazoprevir (GZR)/elbasvir (EBR) treatment in genotype-1b (GT-1b) HCV-infected liver or kidney transplant recipients. In this phase 4, single-arm, open-label, multicenter trial, patients received GZR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amides
Share to Benzofurans

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carbamates

Share to Cyclopropanes

Share to Imidazoles

Share to Kidney Transplantation

Share to Quinoxalines

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 34902265
DOI: 10.1128/AAC.02003-21
PMCID: PMC8846299

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Grazoprevir/Elbasvir Treatment in Liver or Kidney Transplant Recipients with Genotype 1b Hepatitis C Virus Infection.PMID 34902265Read ↗

Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.Semantic proximity Read ↗

Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan.Semantic proximity Read ↗

Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population.Semantic proximity Read ↗

Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system.Semantic proximity Read ↗

The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection.Semantic proximity Read ↗

Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trials.Semantic proximity Read ↗

Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C.Semantic proximity Read ↗

Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan.Semantic proximity Read ↗

Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection.Semantic proximity Read ↗

Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4.Semantic proximity Read ↗

Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study.Semantic proximity Read ↗

Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.